EPZ011989 trifluoroacetate is primarily utilized in research settings as a potent and selective inhibitor of EZH2, a methyltransferase enzyme involved in gene regulation. Its application is significant in studying the role of EZH2 in various cancers, particularly those driven by aberrant histone methylation, such as lymphoma and other malignancies. Researchers use this compound to explore potential therapeutic strategies by targeting EZH2 activity, which is often overexpressed in cancer cells, leading to uncontrolled proliferation. Additionally, it aids in understanding the epigenetic mechanisms underlying tumorigenesis and drug resistance, providing insights for developing novel anticancer therapies. Its specificity and efficacy make it a valuable tool in preclinical studies aimed at advancing precision medicine approaches.